Ipilimumab

A combination of nivolumab, trastuzumab and chemotherapy prolonged PFS and OS among patients with previously untreated, metastatic ERBB2-positive esophagogastric cancer, according to study results published in JAMA Oncology.

CHICAGO — Better health-related quality of life was linked to longer survival in patients with intermediate- or poor-risk renal cell carcinoma, according to an analysis of the CheckMate 214 trial.

In this video, Kim A. Reiss, MD, discussed the results of a randomized phase 1b/2 study of niraparib plus nivolumab or ipilimumab in patients with advanced pancreatic cancer, which were presented in a poster session at ASCO2022.

In the latest installment of Residency to Retirement, experts discussed how physicians can safeguard their assets from inflation. It was the top story in hematology/oncology last week.

Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with unresctable or metastatic urothelial carcinoma whose tumor cells expressed PD-L1 at 1% or greater.

Mark W. Ball, MD, spoke with Healio about an ongoing phase 2 study assessing the use of cytoreductive stereotactic hypofractionated radiotherapy along with ipilimumab and nivolumab in patients with metastatic renal cell carcinoma.

The University of Texas MD Anderson Cancer announced Thursday the launch of the James P. Allison Institute, a research and innovation hub that integrates immunobiology across disciplines to accelerate discoveries toward cancer cures.

SAN FRANCISCO — Certain immune cell-related parameters appeared associated with efficacy of immune checkpoint inhibitors among patients with advanced or metastatic clear cell renal cell carcinoma, according to study results.

Neoadjuvant treatment with nivolumab and ipilimumab led to a high rate of pathologic complete response among patients with resectable microsatellite instability-high/mismatch repair deficient gastric cancers, study results showed.

Combination therapy with nivolumab plus ipilimumab conferred an OS benefit for patients with asymptomatic melanoma brain metastases, according to results of the open-label, phase 2 CheckMate 204 study published in The Lancet Oncology.